Business Wire

Replicor to Disclose Late Breaking HBV Clinical Data at AASLD 2016

Del

Replicor Inc., a privately held biopharmaceutical company targeting a cure for chronic hepatitis B and D patients, today announced that the preliminary interim analysis from its latest REP 401 clinical trial has been selected by the American Association for the Study of Liver Disease (AASLD) for presentation during the late-breaking oral abstract session at its annual meeting to be held November 11-15, 2016 in Boston, U.S.A.

The REP 401 protocol (NCT02565719) is a randomized, controlled trial assessing the safety and efficacy of its first in class HBsAg release inhibitor, REP 2139 and a REP 2139 derivative with improved plasma and tissue clearance (REP 2165) in combination with tenofovir disoproxil fumarate (TDF) and pegylated interferon alpha 2a (peg-IFN) in treatment naïve patients with chronic HBeAg negative HBV infection. The selection of Replicor’s clinical data for presentation during the late breaking oral abstract session on November 15th, 2016 highlights the recognition of NAP-based therapy as an important new approach for achieving functional cure in patients with chronic HBV.

Complete 6 month follow-up data from the REP 301 protocol (NCT02233075) assessing the safety and efficacy of REP 2139 in combination with peg-IFN in patients with chronic HBV / HDV co-infection will also be presented during the poster session on November 14th, 2016.

These presentations will expand on the existing clinical data demonstrating the unique ability of NAP-based combination therapy to eliminate serum HBsAg and to achieve functional cure in patients with HBV and HBV / HDV co-infection.

Replicor’s presentations from AASLD 2016 will be available on the company’s website following their disclosure at the meeting at www.replicor.com/science/conference-presentations. For further information about the 2016 AASLD Meeting visit: http://www.aasld.org/events-professional-development/liver-meeting.

About Replicor

Replicor is a privately held biopharmaceutical company with the most advanced animal and human clinical data in the development of the cure for HBV and HDV. The company is dedicated to accelerating the development of an effective treatment for patients with HBV and HBV/HDV co-infection. For further information about Replicor please visit our website at www.replicor.com.

Contact information

For Replicor Inc.
Alexandra Peterson, 212-508-9709
apeterson@makovsky.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

The Meet Group Announces Closing of Lovoo Acquisition19.10.2017 20:58Pressemelding

The Meet Group, Inc. (NASDAQ: MEET), a public market leader in the mobile meeting space, has completed its acquisition of Lovoo GmbH. The LOVOO app is the most downloaded dating app in Germany, Switzerland, and Austria combined. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171019006572/en/ The Meet Group anticipates this purchase will continue the momentum of its mission to meet the universal need for human connection through innovating, acquiring, and building the largest mobile portfolio of brands for meeting new people. The acquisition is expected to expand The Meet Group’s global footprint, increase the company’s scale and profitability, and diversify its business model by adding expertise in subscription and in-app purchasing. “LOVOO is our third strategic acquisition in the last 12 months, and

Edgewater Networks Announces SD-WAN Optimized for BroadSoft Platforms19.10.2017 20:00Pressemelding

Edgewater Networks, Inc., the market leader in Network Edge Orchestration, announces the upcoming availability of its SD-WAN offering targeted for Small to Medium Enterprises, a key market for service providers offering Unified Communications as a Service. Edgewater Networks’ SD-WAN solution is optimized for the BroadSoft BroadWorks® and BroadCloud® platforms and brings the benefits of this technology to the BroadSoft customer base. “As a new component of our Network Edge Orchestration platform, Edgewater Networks SD-WAN service allows BroadSoft customers to offer comprehensive end user service level agreements by ensuring that real-time communications are automatically routed to the best available Internet connection,” said Chris Kolstad, Edgewater Networks’ Vice President of Product Management. “Edgewater Networks’ SD-WAN offers a new revenue stream to service providers with a soluti

Business Wire Receives Type 2 SOC 2 Attestation Engagement Report Related to Security19.10.2017 19:20Pressemelding

Business Wire today announced that it has successfully completed a Type 2 SOC 2 examination of its BW Connect and HQ systems. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171019006400/en/ The attestation engagement report, conducted by the independent CPA firm Schellman & Company, LLC, confirms that Business Wire has met the standards established by the American Institute of Certified Public Accountants [AICPA] Trust Services Principles related to security. BW Connect is Business Wire’s proprietary web-based order-entry system; HQ provides web-hosting services for online newsrooms, and investor relations hubs for publicly-traded companies. The examination, conducted during the review period February 1, 2017 through July 31, 2017, focused on Business Wire adherence to the Trust Service Principle/Secu

Pharnext: First-Half 201719.10.2017 17:30Pressemelding

Regulatory News: Pharnext SA (FR00111911287 - ALPHA), a biopharmaceutical company pioneering a new approach to the development of innovative drugs based on the combination and repositioning of known drugs, today announced its first-half 2017 financial results. Daniel Cohen, M.D., Ph.D. Co-Founder and CEO said of activity for the first half of 2017: "Activity in the first-half of the year was very dense; we implemented two prominent strategic partnerships with the biotech company Galapagos and the Tasly Group, one of the top ten pharmaceutical companies in China. Our flagship product, PXT3003 for the treatment of Charcot-Marie-Tooth disease type 1A, is nearing the end of Phase 3, which is slated for the second half of 2018. We confirm our target of taking the product to market by 2019." A half-year marked by strategic agreements

Tickets Now on Sale for FEI World Equestrian Games Tryon 2018, North Carolina, USA, on September 11-23, 201819.10.2017 16:58Pressemelding

Tickets for the FEI World Equestrian GamesTM Tryon 2018 (WEG) are now on sale to the public online at www.tryon2018.com. With more than 500,000 people expected to attend the 2018 Games, the 12-day spectacle of equestrian champions is one of the biggest events on the global sporting calendar and will be the largest equestrian event in North Carolina’s history. Mark Bellissimo, CEO of host venue Tryon International Equestrian Center (TIEC) in Tryon, NC, USA, said: “Demand from the event is way beyond our expectations and it would not surprise me if this event were to sell out early. We have experienced unprecedented demand, far bigger than we ever anticipated. There is tremendous appetite for this event, so we encourage people to buy now.” Tickets for the WEG include the following options: a standard Day Pass, Individual Event Pass, All Session Discipline Pas

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom